Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octanate inhibitor incidence study in previously untreated severe hemophilia A patients
2005-004435-22Phase 3Completed
- Sponsor
- Octapharma
- Start
- Nov 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Octanate in hemophilia A, sponsored by Octapharma. Primary endpoint: Occurrence of factor VIII inhibitor activity. Started Nov 2005; status: completed.
02
Drugs
Octanate
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2005-004435-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004435-22.